You just read:

Recent Data Collected by Spherix Global Insights Highlights Key US vs. EU Differences Between Perceptions and Adoption of Eli Lilly's Olumiant and Pfizer's Xeljanz for the Treatment of Rheumatoid Arthritis

News provided by

Spherix Global Insights

Jan 16, 2019, 07:00 ET